The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for GSK’s Zejula (niraparib) as a first-line maintenance treatment in women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of biomarker status.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
